ESR1 and breast carcinoma: Recently, we examined the multi-targeted potential of a monoclonal antibody against mucin 1 (MUC1) and a novel octahydropyrazino[2,1-a:5,4-a′]diisoquinoline derivative (OM-86II) in estrogen receptor-positive MCF-7 human breast cancer cells [48].